Literature DB >> 22035027

Diagnosis and initiation of treatment in Parkinson's disease.

Kelly E Lyons1, Rajesh Pahwa.   

Abstract

Parkinson's disease (PD) is the most common cause of parkinsonism, yet the diagnosis and management can be a challenge. The United Kingdom Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria and dopamine transporter/single-photon emission computed tomography (DaT-SPECT) are diagnostic aids that can improve diagnostic accuracy. Even though PD is a progressive disease, for years, physicians and patients have delayed treatment until functional disability occurs. However, studies of monoamine oxidase-type B (MAO-B) inhibitors, dopamine agonists, and levodopa, all of which can be used as initial therapy, have demonstrated that PD patients receiving treatment do better than those who do not receive treatment, and some studies have shown that those receiving treatment earlier do better long term. Therefore, the management strategy for PD has moved toward earlier initiation of treatment. Although treatment for each patient should be individualized and based on their specific symptoms, severity, and lifestyle, in general MAO-B inhibitors may be used initially to treat mild symptoms, adding a dopamine agonist in younger patients or levodopa in older patients, as symptoms become more severe.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22035027     DOI: 10.3109/00207454.2011.620197

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  4 in total

1.  Transgenic expression of human glial cell line-derived neurotrophic factor from integration-deficient lentiviral vectors is neuroprotective in a rodent model of Parkinson's disease.

Authors:  Ngoc B Lu-Nguyen; Martin Broadstock; Maximilian G Schliesser; Cynthia C Bartholomae; Christof von Kalle; Manfred Schmidt; Rafael J Yáñez-Muñoz
Journal:  Hum Gene Ther       Date:  2014-04-15       Impact factor: 5.695

Review 2.  SPECT molecular imaging in Parkinson's disease.

Authors:  Ling Wang; Qi Zhang; Huanbin Li; Hong Zhang
Journal:  J Biomed Biotechnol       Date:  2012-03-24

3.  Initial medication in patients of newly diagnosed Parkinson's disease in Taiwan.

Authors:  Yi-Jen Guo; Yi-Chu Liao; Ching-Heng Lin; Ming-Hong Chang
Journal:  PLoS One       Date:  2014-09-15       Impact factor: 3.240

4.  Anxiety, depression, and quality of life in Parkinson's disease: the implications of multidisciplinary treatment.

Authors:  Viviana Lo Buono; Rosanna Palmeri; Simona De Salvo; Matteo Berenati; Agata Greco; Rosella Ciurleo; Chiara Sorbera; Vincenzo Cimino; Francesco Corallo; Placido Bramanti; Silvia Marino; Giuseppe Di Lorenzo; Lilla Bonanno
Journal:  Neural Regen Res       Date:  2021-03       Impact factor: 5.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.